Hypereosinophilic Syndrome (HES)

DBCOND0131618Hemic and Lymphatic DiseasesInfections

Hypereosinophilic Syndrome (HES) is the indication for 4 drugs in DrugBank. It is covered by 6 curated, structured indications.

Also known as
Hypereosinophilic Syndrome · Hypereosinophilic Syndromes · HES - Hypereosinophilic Syndrome · Hyper Eosinophilic Syndrome
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0026741ICD-10D72.11SNOMED CT1156250009MedDRA10014947UMLSC0206141

What you can answer from here — as of October 23, 2026

4Indicated drugsWith each drug's targets and mechanism
Listed above
6Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
118Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Drugs reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Hypereosinophilic Syndrome (HES) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In